FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2736153605> ?p ?o ?g. }

• W2736153605 endingPage "406" @default.
• W2736153605 startingPage "394" @default.
• W2736153605 abstract "To evaluate patient-reported outcomes (PROs) of combinations of solifenacin and mirabegron compared with solifenacin and mirabegron monotherapy and with placebo in patients with overactive bladder (OAB) from the SYNERGY trial.Following a 4-week placebo run-in, period patients (≥18 years) with OAB were randomized 2:2:1:1:1:1 to receive solifenacin 5 mg + mirabegron 25 mg (combination 5 + 25 mg), solifenacin 5 mg + mirabegron 50 mg, (combination 5 + 50 mg), solifenacin 5 mg, mirabegron 25 mg, mirabegron 50 mg or placebo for 12 weeks, followed by a 2-week washout period. At each visit, PROs related to quality of life, symptom bother, and treatment satisfaction were assessed, including OAB-q Symptom Bother score, health-related quality of life (HRQOL) Total score, treatment satisfaction-visual analogue scale (TS-VAS), and patient perception of bladder condition (PPBC) questionnaires.Overall, 3527 patients were randomized into the study, with 3494 receiving double-blind treatment. At end of treatment (EoT), both combination groups showed greater improvements in OAB-q Symptom Bother score compared with the monotherapy groups (nominal P < 0.001). Statistically significant improvements in HRQOL Total scores were observed in the combination groups versus monotherapy groups (P ≤ 0.002). For both combination groups, the OAB-q Symptom Bother score responder rates at EoT were statistically significantly higher versus mirabegron monotherapy (P < 0.05). The mean adjusted changes from baseline to EoT for PPBC were greater in the combination groups compared with monotherapy groups.PROs showed that combination therapy provided clear improvements and an additive effect for many HRQOL parameters, including OAB-q Symptom Bother score, HRQOL Total score, and PPBC." @default.
• W2736153605 created "2017-07-21" @default.
• W2736153605 creator A5012263410 @default.
• W2736153605 creator A5016228540 @default.
• W2736153605 creator A5028834947 @default.
• W2736153605 creator A5038167009 @default.
• W2736153605 creator A5046089099 @default.
• W2736153605 creator A5053685634 @default.
• W2736153605 creator A5065452127 @default.
• W2736153605 creator A5073657241 @default.
• W2736153605 creator A5076930803 @default.
• W2736153605 creator A5090695716 @default.
• W2736153605 creator A5091477558 @default.
• W2736153605 creator A5091855331 @default.
• W2736153605 date "2017-07-13" @default.
• W2736153605 modified "2023-10-13" @default.
• W2736153605 title "Patient‐reported outcomes from SYNERGY, a randomized, double‐blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients" @default.
• W2736153605 cites W1547774627 @default.
• W2736153605 cites W1772646200 @default.
• W2736153605 cites W1979747755 @default.
• W2736153605 cites W1986758727 @default.
• W2736153605 cites W1990964605 @default.
• W2736153605 cites W2003411132 @default.
• W2736153605 cites W2010657543 @default.
• W2736153605 cites W2026321185 @default.
• W2736153605 cites W2028950772 @default.
• W2736153605 cites W2051893541 @default.
• W2736153605 cites W2071254580 @default.
• W2736153605 cites W2074760879 @default.
• W2736153605 cites W2075335601 @default.
• W2736153605 cites W2077126096 @default.
• W2736153605 cites W2082897746 @default.
• W2736153605 cites W2108046078 @default.
• W2736153605 cites W2128421946 @default.
• W2736153605 cites W2131770336 @default.
• W2736153605 cites W2134928141 @default.
• W2736153605 cites W2160396622 @default.
• W2736153605 cites W2293202443 @default.
• W2736153605 cites W2332614769 @default.
• W2736153605 cites W2606250578 @default.
• W2736153605 cites W94668587 @default.
• W2736153605 doi "https://doi.org/10.1002/nau.23315" @default.
• W2736153605 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28704584" @default.
• W2736153605 hasPublicationYear "2017" @default.
• W2736153605 type Work @default.
• W2736153605 sameAs 2736153605 @default.
• W2736153605 citedByCount "29" @default.
• W2736153605 countsByYear W27361536052017 @default.
• W2736153605 countsByYear W27361536052018 @default.
• W2736153605 countsByYear W27361536052019 @default.
• W2736153605 countsByYear W27361536052020 @default.
• W2736153605 countsByYear W27361536052021 @default.
• W2736153605 countsByYear W27361536052022 @default.
• W2736153605 countsByYear W27361536052023 @default.
• W2736153605 crossrefType "journal-article" @default.
• W2736153605 hasAuthorship W2736153605A5012263410 @default.
• W2736153605 hasAuthorship W2736153605A5016228540 @default.
• W2736153605 hasAuthorship W2736153605A5028834947 @default.
• W2736153605 hasAuthorship W2736153605A5038167009 @default.
• W2736153605 hasAuthorship W2736153605A5046089099 @default.
• W2736153605 hasAuthorship W2736153605A5053685634 @default.
• W2736153605 hasAuthorship W2736153605A5065452127 @default.
• W2736153605 hasAuthorship W2736153605A5073657241 @default.
• W2736153605 hasAuthorship W2736153605A5076930803 @default.
• W2736153605 hasAuthorship W2736153605A5090695716 @default.
• W2736153605 hasAuthorship W2736153605A5091477558 @default.
• W2736153605 hasAuthorship W2736153605A5091855331 @default.
• W2736153605 hasBestOaLocation W27361536051 @default.
• W2736153605 hasConcept C126322002 @default.
• W2736153605 hasConcept C126894567 @default.
• W2736153605 hasConcept C142724271 @default.
• W2736153605 hasConcept C159110408 @default.
• W2736153605 hasConcept C168563851 @default.
• W2736153605 hasConcept C203092338 @default.
• W2736153605 hasConcept C204787440 @default.
• W2736153605 hasConcept C27081682 @default.
• W2736153605 hasConcept C2776999253 @default.
• W2736153605 hasConcept C2778164427 @default.
• W2736153605 hasConcept C2778941218 @default.
• W2736153605 hasConcept C2779502394 @default.
• W2736153605 hasConcept C2779951463 @default.
• W2736153605 hasConcept C71924100 @default.
• W2736153605 hasConceptScore W2736153605C126322002 @default.
• W2736153605 hasConceptScore W2736153605C126894567 @default.
• W2736153605 hasConceptScore W2736153605C142724271 @default.
• W2736153605 hasConceptScore W2736153605C159110408 @default.
• W2736153605 hasConceptScore W2736153605C168563851 @default.
• W2736153605 hasConceptScore W2736153605C203092338 @default.
• W2736153605 hasConceptScore W2736153605C204787440 @default.
• W2736153605 hasConceptScore W2736153605C27081682 @default.
• W2736153605 hasConceptScore W2736153605C2776999253 @default.
• W2736153605 hasConceptScore W2736153605C2778164427 @default.
• W2736153605 hasConceptScore W2736153605C2778941218 @default.
• W2736153605 hasConceptScore W2736153605C2779502394 @default.
• W2736153605 hasConceptScore W2736153605C2779951463 @default.
• W2736153605 hasConceptScore W2736153605C71924100 @default.
• W2736153605 hasFunder F4320323599 @default.
• W2736153605 hasIssue "1" @default.

• next